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Abstract 
Background: Vildagliptin, a DPP‑4 inhibitor widely used for the treatment of type 2 diabetes mellitus (T2DM), shows 
beneficial effects on endothelial function. This study aims to evaluate the effect of vildagliptin on endothelial function 
and arterial stiffness in patients with T2DM and hypertension.
Methods: Fifty over 35‑year‑old patients with T2DM and hypertension, without cardiovascular disease, will be ran‑
domly allocated to two groups: group 1 will receive vildagliptin added‑on to metformin and group 2, glibenclamide 
added‑on to metformin. Biochemical tests (glycemia, glycated hemoglobin, total cholesterol, high‑density lipoprotein 
cholesterol, triglycerides, creatinine, alanine aminotransferase, ultrasensitive C‑reactive protein, and microalbuminu‑
ria), 24‑h non‑invasive ambulatory blood pressure monitoring, and assessment of endothelial function and arterial 
stiffness will be performed in both groups before and after 12 weeks of treatment. The endothelial function will be 
assessed by peripheral arterial tonometry, which measures the reactive hyperemia index (vasodilation), and arterial 
stiffness will be evaluated by applanation tonometry. All analysis will be performed using SPSS Statistical Software. For 
all analysis, a 2‑sided P < 0.05 will be considered statistically significant.
Results: The study started in December 2013 and patient recruitment is programed until October 2015. The 
expected results are that vildagliptin will improve the endothelial function in patients with T2DM and hypertension 
compared to glibenclamide treatment, independently of glycemic control.
Conclusions: It is expected that this DPP‑4 inhibitor will improve endothelial function in patients with T2 DM.
Trial registration: Clinical Trials NCT02145611, registered on 11 Jun 2013
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Background
Cardiovascular disease (CVD) is the main cause of deaths 
in developing and developed countries. In Brazil, CVD 
accounts for more than 30  % of the overall mortality 
rate and is responsible for 1.2 million hospitalizations/
year [1]. Hypertension (HT) and type 2 diabetes melli-
tus (T2DM) are among the main causes of CVD. Hyper-
tension is the most prevalent of all CVD affecting about 
30–40 % of adults (over 70 million Americans and 36 mil-
lion Brazilians) [2, 3]. The prevalence of T2DM ranges 
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from 13.5 to 15 % of the population [4, 5]. As the num-
ber of elderly population is continuously growing around 
the world, in the next two to three decades there will be 
a 200 % increase in the number of individuals with ages 
>65 years. The prevalence of HT and T2DM is expected 
to increase proportionately [6].
T2DM is associated with a twofold higher risk for CVD 
[7]. Endothelial dysfunction is an independent predictor 
for future CVD in patients with T2DM [8] and is con-
sidered an early marker of vascular complications [9]. It 
is involved in the atherogenesis that occurs in the early 
stages of coronary artery disease (CAD) [10, 11]. The 
mechanisms of impaired endothelial function in diabetes 
are: reduced bioavailability of nitric oxide (NO), dimin-
ished endothelium-dependent vasodilatation, impaired 
barrier function, inflammatory activation, and a pro-
coagulant state [12].
Today, some groups of drugs that act on the incretin 
system, such as glucagon-like peptide-1 (GLP-1) ana-
logues/agonists and dipeptidyl peptidase-4 enzyme 
(DPP-4) inhibitors, are used to treat T2DM and may be 
responsible for beneficial effects on endothelial function 
[13].
Incretins such as GLP-1 and glucose-dependent insu-
linotropic polypeptide (GIP) belong a group of gastro-
intestinal hormones that stimulate insulin secretion 
in response to the ingestion of food [13]. There is evi-
dence of physiological signaling by GLP-1 in endothelial 
and vascular smooth muscle cells [14–16]. GLP-1 has a 
vasodilator action mediated through a specific GLP-1 
receptor in the vascular endothelium and may improve 
endothelial function in animals and humans [14, 16]. 
However, cardiovascular effects may be GLP-1 receptor-
independent, and mediated by the metabolites of GLP-1 
[17]. One study with exenatide, a GLP-1 agonist, showed 
a significant increase in flow-mediated vasodilatation 
(FMD) [18]. Moreover, liraglutide, a GLP-1 analogue, 
reduced plasminogen activator inhibitor 1 (PAI-1) and 
asymmetric dimethylarginine (ADMA) levels, thereby 
improving nitric oxide availability [19]. Other researchers 
found increases in global myocardial blood flow follow-
ing GLP-1 agonist infusions in T2DM [20], and following 
GLP-1 infusions in healthy humans [21].
On the other hand, DPP-4 rapidly degrades incretin 
hormones to inactive metabolites [13] thus DPP-4 inhibi-
tors may improve endothelial function. Studies with sit-
agliptin, a DPP-4 inhibitor, demonstrated an increase of 
endothelial progenitor cells in T2DM by inhibiting the 
degradation of the chemokine stromal-derived factor 
1-α [22]. According to an invasive method used to meas-
ure forearm blood flow during acetylcholine infusion in 
T2DM patients, vildagliptin, another DPP-4 inhibitor, 
improved endothelium-dependent vasodilatation [23]. 
In contrast, other studies did not demonstrate beneficial 
effects in relation to the endothelium [24, 25].
Recently, three large multicenter, randomized trials 
testing saxagliptin [26], alogliptin [27], and sitagliptin 
[28] did not find any reduction in cardiovascular events, 
but these drugs did not increase the risk of the primary 
end-point either. However, the rate of hospitalization 
for heart failure increased in the saxagliptin arm of the 
SAVOR study [26]. Thus, the researchers concluded that 
GLP-1 inhibitors are safe for patients with CVD.
Several methods have been used to assess impaired 
endothelial function including plasma concentrations of 
markers of endothelial activity, vessel structure related to 
the carotid intima media thickness and arterial stiffness, 
flow-mediated vasodilation (FMD) and peripheral arte-
rial tonometry (PAT).
PAT is a simple, non-invasive, and reproducible tech-
nique used to assess endothelial function [29]. Measure-
ments of PAT in patients with CAD have been shown 
to strongly correlate with the parameters of endothelial 
dysfunction [30–33]. The Endo-PAT is an observer-inde-
pendent technique that measures volume changes in the 
fingertip before and after blood flow occlusion and auto-
matically calculates the reactive hyperemia index (RHI), 
providing an index for endothelial function.
Arterial stiffness is another parameter used to inves-
tigate endothelial dysfunction. It is recognized as a car-
diovascular risk marker [34] as impaired endothelial 
function is one of the mechanisms involved in increased 
vascular stiffness [35]. Patients with both HT and T2DM 
exhibit increased arterial stiffness compared to those 
with either T2DM or HT alone [36]. Arterial stiffness 
parameters predict clinical outcomes (CAD, stroke, uri-
nary albumin excretion, progression of chronic kidney 
disease, survival in end-stage renal disease and general 
cardiovascular risk) [37–42] and have a greater impor-
tance in clinical prognoses compared to other known car-
diovascular risk factors such as age, gender, smoking, and 
dyslipidemia [43]. The non-invasive applanation tonom-
etry technique assesses arterial stiffness by estimating 
arterial compliance and central blood pressure (BP) and 
calculates the augmentation index (AIx) [44–46]. The AIx 
is a marker of wave reflection derived from aortic pres-
sure wave analysis, with increased AIx being correlated 
to increased stiffness and contributing to cardiovascular 
risk [37, 43]. Evidence shows that the central blood pres-
sure is more relevant to cardiovascular outcomes than 
the BP in the brachial artery [47–49]. More recently, a 
study demonstrated improvement in central BP and AIx 
following the use of vildagliptin in a patient with T2DM 
and HT [50].
Thus, using the non-invasive Endo-PAT 2000 device 
and radial artery applanation tonometry, the purpose of 
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this study is to evaluate the effect of vildagliptin com-
pared to glibenclamide both added-on to metformin on 
endothelial function and arterial stiffness in patients with 
T2DM and hypertension.
Methods
The present trial (clinicaltrials.gov identifier: 
NCT02145611) will be randomized, open label, parallel 
assignment, controlled by drug. It was designed to assess 
the effect of vildagliptin (100 mg/day b.i.d.) on endothe-
lial function in patients with T2DM and hypertension 
compared to glibenclamide (5–20  mg/day depending 
on glycemic control). The Research Ethics Committee 
of the institution approved the study protocol accord-
ing to national and international guidelines. All patients 
will give their informed consent. Twenty-five individu-
als with T2DM and hypertension will be evaluated in the 
vildagliptin plus metformin group compared to 25 dia-
betic and hypertensive subjects in the glibenclamide plus 
metformin group. Figure  1 shows a flow chart of par-
ticipant selection and interventions. The inclusion and 
exclusion criteria are presented in Table 1.
Random allocation
A computer validated software (Random allocator) will 
be used for random allocation. The study coordinator 
will organize and number the envelopes which will be 
allocated in order of patient enrollment. The professional 
responsible for the Endo-PAT procedure and applanation 
tonometry of radial artery will be blinded.
Randomization and follow‑up
After screening for eligibility, 50 individuals will be sub-
mitted to an evaluation of endothelial function using the 
Endo-PAT 2000 device and measurement of the arte-
rial stiffness by applanation tonometry of radial artery. 
Subsequently, they will be randomly allocated to the 
two arms of the study: Group 1 will receive vildagliptin 
1. Hemodynamic evaluation  
2. Endothelial function 
3. Arterial stiffness 
N=25 (vildagliptin group) N=25 (glibenclamide group) 
Glibenclamide + Metformin 
Treatment  
for 12 weeks 
________________ 
Physical examination and 
Biochemical tests
1. Hemodynamic evaluation 
2. Endothelial function 
3. Arterial stiffness 




Physical examination and 
Biochemical tests
1. Clinical hystory 
2. Physical examination 
3. Screening with: 
biochemical tests and 
treadmill test or myocardial 
scintigraphy or coronary 
angiography 
1. Hemodynamic evaluation
2. Endothelial function 
3. Arterial stiffness 
1. Hemodynamic evaluation
2. Endothelial function 
3. Arterial stiffness 
Fig. 1 Flowchart of Study
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(100  mg/day b.i.d.) added-on to metformin (500–
2550  mg/day according to glycemic control) and Group 
2 will receive glibenclamide (5–20  mg/day according to 
glycemic control) added-on to metformin (500–2550 mg/
day according to glycemic control). Blood samples will be 
collected after 12-h overnight fasting at screening visit 
and then after 12  weeks of treatment with vildagliptin 
(Group 1) or glibenclamide (Group 2). Renin-angiotensin 
system blockers will be prescribed to all subjects at the 
screening visit and all other antihypertensive drugs will 
be maintained. Subjects will have three return consulta-
tions. The first will be to randomize patients to Group 1 
or 2 and they will be evaluated after four and 12 weeks. 
Compliance will be monitored by pill counts at the sec-
ond and last visits. The glycemic control will be evalu-
ated by glycated hemoglobin and fasting glucose. Adverse 
events will be evaluated on the basis of spontaneous 
reports and interviews by the investigator. Considering 
side effects and safety, nausea, upper abdominal pain and 
flatulence are expected, although uncommon, while tak-
ing vildagliptin. The most frequent side effect of gliben-
clamide is hypoglycemic events. Changes in blood count, 
renal function, and liver function are not expected with 
either treatment.
Table 2 shows a summary of key practical aspects of the 
study with all follow-up visits and requested exams.
Anthropometric measurements
Weight and height will be measured using metric weigh-
ing scales and a measuring tape and the body mass index 
(BMI) will be obtained using the formula: BMI = weight 
(kg)/(height in meters)2. The waist circumference will be 
determined in centimeters using a measuring tape. This 
measurement will be carried out midway between the 
anterior superior iliac crest and the last rib at the end of 
expiration.
Measurement of blood pressure
BP will be measured in the office using a digital sphyg-
momanometer according to the VI Brazilian Guidelines 
on Hypertension Treatment [51]. Systolic (SBP) and 
diastolic blood pressure (DBP) will be recorded. Hyper-
tension will be defined as a SBP  ≥  140  mmHg and/or 
a DBP ≥  90  mmHg or current use of anti-hypertensive 
drugs.
Biochemical tests
Blood samples will be drawn after 12  h of fasting to 
measure total cholesterol (TC), high-density lipoprotein 
cholesterol (HDLc), triglycerides (TG), glycemia, serum 
creatinine, alanine aminotransferase, glycated hemo-
globin and ultrasensitive C-reactive protein (CRP). Tur-
bidimetry (BioSystems) will be used to measure the CRP 
and the possibility of patients having had acute infec-
tious or inflammatory processes within recent weeks will 
be excluded. Microalbuminuria will also be evaluated. To 
evaluate microalbuminuria, the urinary albumin-to-cre-
atinine ratio (UACR) will be obtained from urine sam-
ples collected in the morning. Urine creatinine will be 
calculated using a colorimetric method, and albuminuria 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients aged ≥35 years Use of NPH or regular insulin, pioglitazone, GLP‑1 receptor agonist, DPP‑4 
inhibitor or acarbose
History of DM and mild hypertension (blood pressure <160/100 mmHg)  
no longer than 15 years
Intolerance to metformin
Body mass index <35 kg/m2 Use of three or more anti‑hypertensive drugs, which characterizes resistant 
hypertension
Glycated hemoglobin (HbA1c) between 7.0 and 10.5 % Smoking within the previous 6 months
Pregnancy or breastfeeding
Creatinine clearance <45 mL/min (MDRD)
Serum alanine aminotransferase or aspartate aminotransferase level of 
more than three times the upper limit of the normal range
Subjects with ischemic heart disease, cerebrovascular disease, other 
atherosclerotic disease, cancer, or heart failure in functional classes II, III 
and IV
Treadmill stress test with typical chest pain or with ST segment depression 
≥1 mm, or with a horizontal or descending trace on the electrocardio‑
gram for a duration of 0.08 s after the J point
Presence of coronary heart disease diagnosed by treadmill stress test, myo‑
cardial scintigraphy or coronary angiography
Inability to give informed consent
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will be determined using the nephelometric method. 
The glomerular filtration ratio (GFR) will be estimated 
using the Modification of Diet in Renal Disease (MDRD) 
formula: GFRMDRD (mL/min/1.73 m2) = 186 (serum cre-
atinine)−1.154 × (age)−0.203 × (0.742 if female) × (1.212 if 
black) [52].
Diabetic subjects will be identified by history of 
diabetes with dietetic treatment for diabetes or the 
use of hypoglycemic drugs. Subjects will be consid-
ered diabetics after two fasting glucose test results 
greater than 125  mg/dL according to the National 
Diabetes Data Group [53]. Serum cholesterol will be 
evaluated according to the Brazilian Guidelines for 
Dyslipidemias [54]. Low-density lipoprotein choles-
terol (LDLc) will be calculated using the Friedewald 
formula for triglycerides levels below 400  mg/dL 
(LDLc = TC − HDLc − TG/5) [55].
Evaluation of coronary artery disease
At the first (screening) visit, all selected subjects will be 
evaluated for CAD using the treadmill stress test. Sub-
jects with abnormal stress test results, including typi-
cal chest pain, with ST segment depression ≥1  mm, or 
with a horizontal or descending trace on the electrocar-
diogram for a duration of 0.08 s after the J point, will be 
excluded. When necessary, individuals will be submitted 
to other tests to evaluate CAD, such as myocardial scin-
tigraphy and coronary angiography.
Measurement of blood pressure including 24‑h 
ambulatory blood pressure monitoring
After randomization and again after 12  weeks of treat-
ment with vildagliptin (Group 1) or glibenclamide 
(Group 2), 24-h non-invasive ambulatory blood pressure 
monitoring (ABPM) will be performed on a workday with 
a portable compact digital BP recorder (Mobil-O-Graph® 
24-hour PWA monitor).
Automatic BP measurements will be recorded at 
20-min intervals for diurnal readings (7.00  a.m.–
11.00  p.m.) and at 30-min intervals for nocturnal read-
ings (11.00  p.m.–7.00  a.m.). Nighttime and daytime 
periods will be assessed based on information reported 
by the subjects. The sleep BP will be defined as the mean 
BP from the time the subjects go to bed until the time 
they get up. The daytime BP will be defined as the average 
BP during the rest of the day. The subjects will be divided 
into two groups according to the dip in SBP during the 
nighttime: participants will be considered as dippers, if 
the decrease in sleep SBP is ≥10 % and non-dippers if the 
decrease is <10 %. As part of the exam protocol, all par-
ticipants will be requested to make a note of their daily 
activities, their meal times, times of sleeping and waking 
Table 2 Key practical aspects of the study with all the clinical visits and the requested exams
Visits Screening Visit 1 Visit 2 Visit 3
Weeks −1 1 4 12
Informed consent X
Inclusion and exclusion criteria X X
Medical history X
Medical evaluation/physical examination X X X X
Randomization X
 Pregnancy test X
 Creatinine X X
 Fasting glucose X X X
 Ultrasensitive C‑reactive protein X X
 Total cholesterol X X
 High‑density lipoprotein cholesterol X X
 Triglycerides X X
 Glycated hemoglobin X X
 Alanine aminotransferase X X
 Microalbuminuria X X
 Ambulatory blood pressure monitoring X X
 Treadmill test X
 Determination of the central aortic pressure and vascular stiffness markers X X
 Endothelium function X X
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up, as well as time of taking medications and the pres-
ence of symptoms.
Vascular tests
Vascular tests will be performed in the subjects of both 
groups at the first visit and after 12 weeks of treatment.
1. Determination of endothelial function
Peripheral arterial tonometry (Endo-PAT 2000; Itamar 
Medical, Caesarea, Israel) is a non-invasive peripheral 
test of endothelial function [32]. The PAT device is placed 
on the tip of each index finger and comprises a pneu-
matic plethysmograph that applies a uniform pressure to 
the surface of the distal finger, allowing measurement of 
pulse volume changes. The inflation pressure of this dig-
ital device is electronically set at 10  mmHg below DBP 
or 70 mmHg. The PAT signal is recorded at baseline and 
then after 5 min of arterial occlusion using an inflatable 
cuff, while the contralateral arm serves as a control. The 
blood pressure cuff is inflated to 60 mmHg higher than 
systolic pressure or at least 200  mmHg. Lack of resid-
ual pulsatility is monitored throughout the occlusion 
period. Post-occlusive hyperemia stimulates endothe-
lium-dependent vasodilatation, causing an increase in 
digital pulse amplitude. Pulse amplitude is recorded elec-
tronically in both fingers and analyzed by an automated, 
computerized algorithm (Itamar Medical). The change 
from the baseline measurement is expressed as the RHI, 
which, in part, reflects vasodilator function of the digital 
microcirculation.
Subjects will be instructed to fast the night before test-
ing and to refrain from ingesting alcohol or caffeine. The 
room temperature will be maintained between 21 and 
24  °C at all times during the exam; restrictive clothing, 
watches, rings, or other jewelry on the hands that might 
interfere with blood flow will be removed. The test will 
be performed in the morning after the patient has been 
comfortably seated or has laid down in the study room for 
at least 15 min to reach a relaxed cardiovascular steady-
state [31, 32]. The subjects of the study will be submitted 
to the endothelial function test at their first visit and after 
12  weeks of treatment. Endothelial dysfunction will be 
defined as a RHI ≤ 1.68, according to a study performed 
in healthy asymptomatic control individuals without his-
tory of CVD and without major risk factors [56].
2. Determination of the central aortic pressure and vas-
cular stiffness
Arterial stiffness, assessed using the non-invasive 
method of radial artery applanation tonometry, is predic-
tive of vascular disease. A portion of the artery pressure 
wave travelling towards the extremities is reflected back 
by peripheral impedance points. In healthy individuals, 
the reflected wave returns to the aorta during diastole. 
However, when arteries become stiff, the transit time 
between the incident and reflected waves is reduced. 
Thus, the reflected wave returns to the aorta during sys-
tole of the same cardiac cycle thereby augmenting the 
central BP. This elevation of the central BP can be quan-
tified using the AIx [57, 58]. The AIx is associated with 
cardiovascular risk, and predicts the presence or absence 
of CAD [59]. Higher values of the AIx indicate increased 
wave reflection from peripheral vessels or earlier return 
of the reflected wave as a result of increased pulse wave 
velocity, which is attributed to an increased arterial stiff-
ness. In young healthy individuals, the systolic arterial 
pressure (aortic) is about 15–20  mmHg lower than the 
peripheral systolic pressure (brachial) [45, 60].
Outcomes and outcome adjudication
1. Change in the RHI from baseline after 12  weeks of 
vildagliptin vs. glibenclamide treatment.
2. Change in the central blood pressure from baseline 
to after 12  weeks of vildagliptin vs. glibenclamide 
treatment.
Statistical considerations
Sample size and power calculations
The site http://www.lee.dante.br-pesquisa was used to 
estimate the sample size, considering a 30  % change in 
the RHI between treatment groups as clinically relevant. 
Assuming a standard deviation of 0.3 would require a 
total of 21 subjects to detect a 30  % change in the RHI 
with a power of 80 % at a significant level of 0.05. How-
ever, considering a potential 20 % of drop-out or lost to 
follow-up rate, a total of 50 patients (25 for each group) 
will be considered.
Statistics
All analysis will be performed using SPSS Statistical Soft-
ware (IBM SPSS Statistics for Windows, Version 21.0. 
Armonk, NY: IBM Corp.). Continuous variables will 
be presented as mean  ±  SD and categorical variables 
as frequencies. Differences between the both groups 
at baseline will be evaluated by unpaired t test or the 
Mann–Whitney test for comparison of continuous vari-
ables. The Chi square test or Fisher’s exact test will be 
employed to compare categorical variables. The change 
from baseline to 12-weeks follow-up in the both groups 
will be evaluated using the paired t test for continuous 
variables. Pearson’s correlation will be used to assess 
the relationship between HbA1c and RHI and AIx, after 
confirmation of similarity between groups in respect to 
demographic data (age, gender, GFR, and comorbidities: 
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hypertension and dyslipidemia) and HbA1c targets after 
12  weeks of considered treatment. Thus, the Pearson’s 
correlation obtained will be potentially consequent to 
distinct therapeutic responses. For all analysis, a 2-sided 
P < 0.05 will be considered statistically significant.
Results/discussion
The study has started in December 2013 and patient 
recruitment is programed until October 2015. It is 
expected that vildagliptin will improve the endothelial 
function in patients with T2DM and hypertension more 
than glibenclamide treatment. Hyperglycemia causes 
endothelial dysfunction because it reduces the bio-
availability of endothelium-derived nitric oxide (NO). 
Although the main action of GLP-1 is to increase glu-
cose-stimulated insulin secretion from pancreatic beta 
cells, there is also evidence of physiological signaling 
from GLP-1 in endothelial and vascular smooth muscle 
cells. Thus, GLP-1 has vasodilator actions mediated by a 
specific GLP-1 receptor in the vascular endothelium and 
may improve endothelial function in animals and humans 
[15–17], independently of its effect on glycemic control.
Arterial stiffness is recognized as another cardio-
vascular risk marker [32]. Patients with both HT and 
DM exhibit higher arterial stiffness compared to those 
with either DM or HT alone [33]. Applanation tonom-
etry estimates arterial compliance and the central blood 
pressure and is used to assess arterial stiffness [42, 43]. 
Evidence shows that the central blood pressure is more 
relevant to cardiovascular outcomes than the peripheral 
BP [44–46]. On the other hand, Endo-PAT, a non-inva-
sive method, evaluates the vascular vasodilator propriety 
and, consequently, endothelial function. Both hypoglyce-
mic drugs, vildagliptin and glibenclamide, may improve 
glycemic control. However, only vildagliptin and other 
DPP-4 inhibitors have provided beneficial effects of the 
endothelium [22, 23].
Conclusions
This study will evaluate the effect of vildagliptin com-
pared to glibenclamide, both added-on to metformin, on 
endothelial function and arterial stiffness in type 2 dia-
betic patients with hypertension. The improvement of 
endothelial function will demonstrate that DPP-4 inhibi-
tors could improve cardiovascular outcome, especially in 
high cardiovascular risk patients.
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